Schlack K - Search Results

1

Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?

Klaile Y, Schlack K, Boegemann M, Steinestel J, Schrader AJ, Krabbe LM. Klaile Y, et al. Among authors: schlack k. Transl Androl Urol. 2016 Oct;5(5):692-701. doi: 10.21037/tau.2016.06.13. Transl Androl Urol. 2016. PMID: 27785426 Free PMC article. Review.

2

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.

Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M, Eckstein M. Klümper N, et al. Among authors: schlack k. Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764. Clin Cancer Res. 2023. PMID: 36534531 Free PMC article.

3

The safety and efficacy of gemcitabine for the treatment of bladder cancer.

Schlack K, Boegemann M, Steinestel J, Schrader AJ, Krabbe LM. Schlack K, et al. Expert Rev Anticancer Ther. 2016;16(3):255-71. doi: 10.1586/14737140.2016.1143777. Epub 2016 Feb 9. Expert Rev Anticancer Ther. 2016. PMID: 26781169 Review.

4

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.

Boegemann M, Schlack K, Fischer AK, Gerß J, Steinestel J, Semjonow A, Schrader AJ, Krabbe LM. Boegemann M, et al. Among authors: schlack k. PLoS One. 2016 Sep 1;11(9):e0161959. doi: 10.1371/journal.pone.0161959. eCollection 2016. PLoS One. 2016. PMID: 27583544 Free PMC article.

5

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer.

Schlack K, Krabbe LM, Fobker M, Schrader AJ, Semjonow A, Boegemann M. Schlack K, et al. Int J Mol Sci. 2016 Sep 9;17(9):1520. doi: 10.3390/ijms17091520. Int J Mol Sci. 2016. PMID: 27618028 Free PMC article.

6

The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.

Boegemann M, Schlack K, Thomes S, Steinestel J, Rahbar K, Semjonow A, Schrader AJ, Aringer M, Krabbe LM. Boegemann M, et al. Among authors: schlack k. Int J Mol Sci. 2017 Feb 11;18(2):380. doi: 10.3390/ijms18020380. Int J Mol Sci. 2017. PMID: 28208664 Free PMC article.

7

Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving ¹⁷⁷Lu-PSMA-617.

Kessel K, Seifert R, Schäfers M, Weckesser M, Schlack K, Boegemann M, Rahbar K. Kessel K, et al. Among authors: schlack k. Theranostics. 2019 Jul 9;9(17):4841-4848. doi: 10.7150/thno.35759. eCollection 2019. Theranostics. 2019. PMID: 31410185 Free PMC article.

8

A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting.

Boegemann M, Schlack K, Früchtenicht L, Steinestel J, Schrader AJ, Wennmann Y, Krabbe LM, Eminaga O. Boegemann M, et al. Among authors: schlack k. Oncotarget. 2019 Aug 20;10(49):5082-5091. doi: 10.18632/oncotarget.27133. eCollection 2019 Aug 20. Oncotarget. 2019. PMID: 31489117 Free PMC article.

9

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis.

Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, Fendler WP, Hadaschik B, Kleesiek J, Schäfers M, Weckesser M, Boegemann M, Rahbar K. Seifert R, et al. Among authors: schlack k. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1200-1210. doi: 10.1007/s00259-020-05040-1. Epub 2020 Sep 24. Eur J Nucl Med Mol Imaging. 2021. PMID: 32970216 Free PMC article.

10

Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry.

Boegemann M, Schlack K, Rink M, Bernhardt S, Moran M, Hubbe M, Bergmann L, Schmid M, Strauss A. Boegemann M, et al. Among authors: schlack k. Future Oncol. 2020 Dec;16(35):2939-2948. doi: 10.2217/fon-2020-0548. Epub 2020 Oct 6. Future Oncol. 2020. PMID: 33021843 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page